Estalis® Gynecology A dermal patch containing estradiol/norethindrone acetate used to manage the vasomotor Sx of menopause; vulvar and vaginal atrophy; hypoestrogenism due to hypogonadism, castration, or primary ovarian failure
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.
References in periodicals archive ?
* estradiol and norethindrone acetate patch (CombiPatch)
* Estraderm and CombiPatch (Novartis) for menopausal symptoms
Novogyne manufactures the hormone therapy patches, Vivelle-Dot, Vivelle, and CombiPatch.
Novogyne manufactures the hormone therapy patches Vivelle-Dot, Vivelle, and CombiPatch.
(17.) Archer DF, Furst K, Tipping, et al for the Combipatch Study Group.
Climara Pro delivers a lower dose of estradiol (0.045 mg/day of estradiol and 0.015 mg/day of levonorgestrel) than CombiPatch, the first estrogen and progestin patch on the U.S.
Climara Pro delivers a lower dose of estradiol (0.045 rag/day of estradiol and 0.015 rag/day of levonorgestrel) than CombiPatch, the first estrogen and progestin patch on the U.S.
Drug Dosage conjugated equine estrogen and 0.625 mg estrogen and medroxyprogesterone acetate 2.5 mg medroxyproges- (Prempro) terone/day estradiol and norethindrone 1 mg estradioland acetate (Activella) 0.5 mg norethindrone/day ethinyl estradiol and norethindrone 5 [micro]g ethinyl acetate (femhrt) estradiol and 1 mg norethindrone/day estradiol and norethindrone 0.05 mg estradiol and acetate (CombiPatch) 0.14 mg norethindrone/ day estradiol and norgestimate (Ortho- 1 mg estradiol/day and Prefest) 0.09 mg norgestimate/day for 3 days.
For menopausal women with an intact uterus, CombiPatch (estradiol/norethindrone acetate) transdermal system relieves such moderate-to-severe vasomotor symptoms as hot flashes, night sweats and vaginal dryness, according to Gary Shearman, the company's senior vice president of development and deputy head of research and development.
Before the debut of CombiPatch women who would benefit from both estrogen and progestin were prescribed either oral estrogen and progestin or an estrogen transdermal patch used In conjunction with oral progestin.
"The approval of CombiPatch represents a major advance in the treatment of menopausal vasomotor symptoms -- a win for patients and for physicians, who now have a new hormone replacement therapy option to offer patients," Shearman says.
* Comment: In studies of postmenopausal women, those treated with CombiPatch had a significant reduction in the number and intensity of daily hot flashes, compared with those on placebo.